D-0112-2024 Class III Terminated

Recalled by Glenmark Pharmaceuticals Inc., USA — Mahwah, NJ

FDA drug recall D-0112-2024 was initiated by Glenmark Pharmaceuticals Inc., USA on Oct 23, 2023 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications:Out of Specification result reported for the test of organic impurities for the drug product,at the 18 month time point in long term stability study… The recall status is terminated (terminated Jul 5, 2024). Affected quantity: 8,448 30-count bottles, 168 1000-count bottles.

Recall details

Product Type
Drugs
Report Date
Nov 29, 2023
Initiation Date
Oct 23, 2023
Termination Date
Jul 5, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
8,448 30-count bottles, 168 1000-count bottles

Product description

Esomeprazole Magnesium Delayed-Release Capsules, USP 20mg, Packaged as (a) 30-count bottle, NDC 68462-390-30; (b) 1000-count Bottle, NDC 68462-390-10: RX Only, Manufactured for: Glenmark, Pharmaceuticals Inc., USA, Mahwah, NJ 07430, Product of India,

Reason for recall

Failed Impurities/Degradation Specifications:Out of Specification result reported for the test of organic impurities for the drug product,at the 18 month time point in long term stability study (25¿C/60% RH).

Distribution pattern

Nationwide in the USA

Code information

Lot # 17220002, Exp Date 11/30/2023

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0112-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0112-2024. Report a data issue: hello@regdatalab.com.